Markets:

Overview

News

Currencies

International

Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

35.00 +0.74 (+2.16%)

Streaming Delayed Price Updated: 11:59 AM EDT, Apr 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

31 32 Next >

Viking Therapeutics Is Having a Year to Remember: Time to Buy?

September 19, 2024

Viking Therapeutics Inc. (NASDAQ: VKTX) has surged 238% year-to-date and 326% over the past year, far outpacing its sector and market.

Via MarketBeat

This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments ↗

September 18, 2024

Terns has a modest market cap of less than $800 million, and its possible upside could be massive.

Via The Motley Fool

Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030 ↗

September 18, 2024

These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.

Via The Motley Fool

What the Options Market Tells Us About Viking Therapeutics ↗

September 17, 2024

Via Benzinga

1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc) ↗

September 17, 2024

Telemedicine once seemed like it was going to revolutionize healthcare.

Via The Motley Fool

Viking Therapeutics Unusual Options Activity For September 11 ↗

September 11, 2024

Via Benzinga

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $7,500 Today ↗

September 06, 2024

Via Benzinga

(VKTX) - Analyzing Viking Therapeutics's Short Interest ↗

August 21, 2024

Via Benzinga

Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now. ↗

September 15, 2024

Terns Pharmaceuticals just proved that it's competitive in the weight loss field.

Via The Motley Fool

Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review ↗

September 13, 2024

The major indexes reclaimed key levels and many leaders flashed buy signals.

Via Investor's Business Daily

These 2 Biotech Stocks Are Set to Soar ↗

September 13, 2024

Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins.

Via The Motley Fool

Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735 ↗

September 13, 2024

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right track.

Via The Motley Fool

Why Investors Plowed Into Viking Therapeutics Stock Today ↗

September 12, 2024

The company is looking especially good after some bad news coming from a rival.

Via The Motley Fool

Unpacking the Latest Options Trading Trends in Viking Therapeutics ↗

August 20, 2024

Via Benzinga

3 No-Brainer Biotech Stocks to Buy With $200 Right Now ↗

September 12, 2024

An investment in these players today could score a big win down the road.

Via The Motley Fool

Why Viking Therapeutics Stock Rocked the Market Today ↗

September 11, 2024

The biotech continued to get attention from both pundits and investors, thanks largely to its investigational obesity drug.

Via The Motley Fool

Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan ↗

September 11, 2024

JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics with an Overweight rating and a December 2025 price target of $80.

Via Benzinga

Novo Nordisk Jumps After New Weight-Loss Pill Tops Wegovy; Eli Lilly, Viking Shares Rise ↗

September 11, 2024

The company is working on a drug that targets GLP-1 and amylin to improve weight loss.

Via Investor's Business Daily

Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead? ↗

September 07, 2024

The huge demand for effective new weight management drugs has billionaire investors feeling bullish about this stock.

Via The Motley Fool

Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern ↗

September 05, 2024

Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation. Other drugs also affected.

Via Benzinga

Prediction: This Biotech Stock Will Outperform Nvidia in the Second Half of the Year ↗

September 05, 2024

Nvidia is heading for a 118% gain this year.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 03, 2024

Via Benzinga

The Best Biotech Stock to Invest $1,000 in Right Now ↗

September 03, 2024

This business has solid results in hand, lots of cash, and more catalysts coming.

Via The Motley Fool

The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race ↗

August 29, 2024

The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots.

Via Investor's Business Daily

Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics ↗

August 29, 2024

Jim Cramer discusses Serve Robotics, Builders FirstSource, Vertex Pharmaceuticals and Viking Therapeutics on CNBC.

Via Benzinga

Why Viking Therapeutics Stock Got Thrashed on Tuesday ↗

August 27, 2024

A monster rival is making aggressive moves in one particular segment.

Via The Motley Fool

Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug ↗

August 27, 2024

The single-dose vials will also increase supply, the drug giant says.

Via Investor's Business Daily

Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030 ↗

August 26, 2024

The companies are chasing major innovations.

Via The Motley Fool

Viking Therapeutics Stock Could Rocket 76% Higher According to Wall Street. Is It a Buy Now? ↗

August 26, 2024

The new drugs this company is developing could be worth a lot more than the present market value of its stock.

Via The Motley Fool

Big Pharma Stocks: Who’s Leading The Race And Who’s Slipping? ↗

August 20, 2024

Merck's wider drug moat and acquisition spree makes it a safer bet but VKTX can be the next LLY.

Via Talk Markets

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

31 32 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.